National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Addiction. 2022 Aug;117(8):2157-2167. doi: 10.1111/add.15786. Epub 2022 Jan 24.
To compare quantitatively the efficacy and tolerability of pharmacologically active interventions in the treatment and prevention of alcohol-induced hangover.
Systematic review of placebo-controlled randomised trials in healthy adults that evaluated any pharmacologically active intervention in the treatment or prevention of hangover. We searched Medline, Embase, PsycINFO and CENTRAL from database inception until 1 August 2021. The primary efficacy outcome was any continuous measure of overall hangover symptoms and the primary tolerability outcome the number of people dropping out because of adverse events (AEs). Quality was assessed using the Grading of Recommendations Assessment Development and Evaluation (GRADE) framework.
A total of 21 studies were included reporting on 386 participants. No two studies reported on the same intervention; as such, meta-analysis could not be undertaken. Methodological concerns and imprecision resulted in all studied efficacy outcomes being rated as very low quality. When compared with placebo, individual studies reported a statistically significant reduction in the mean percentage overall hangover symptom score for clove extract (42.5% vs 19.0%, P < 0.001), tolfenamic acid (84.0% vs 50.0%, P < 0.001), pyritinol (34.1% vs 16.2%, P < 0.01), Hovenia dulcis fruit extract (P = 0.029), L-cysteine (P = 0.043), red ginseng (21.1% vs 14.0%, P < 0.05) and Korean pear juice (41.5% vs 33.3%, P < 0.05). All studied tolerability outcomes were of low or very low quality with no studies reporting any drop-outs because of AEs.
Only very low quality evidence of efficacy is available to recommend any pharmacologically active intervention for the treatment or prevention of alcohol-induced hangover. Of the limited interventions studied, all had favourable tolerability profiles and very low quality evidence suggests clove extract, tolfenamic acid and pyritinol may most warrant further study.
定量比较药理学活性干预措施在治疗和预防酒精性宿醉中的疗效和耐受性。
系统评价健康成年人中安慰剂对照随机试验，评估任何药理学活性干预措施在治疗或预防宿醉中的作用。我们检索了 Medline、Embase、PsycINFO 和 CENTRAL 数据库，检索时间从数据库建立到 2021 年 8 月 1 日。主要疗效结局是任何总体宿醉症状的连续测量指标，主要耐受性结局是因不良事件（AE）而退出的人数。使用推荐评估、制定与评价（GRADE）框架评估质量。
共纳入 21 项研究，共纳入 386 名参与者。没有两项研究报告了相同的干预措施；因此，无法进行荟萃分析。方法学问题和不精确性导致所有研究的疗效结局均被评为极低质量。与安慰剂相比，个别研究报告说，丁香油提取物（42.5%比 19.0%，P<0.001）、托芬那酸（84.0%比 50.0%，P<0.001）、吡硫醇（34.1%比 16.2%，P<0.01）、枳椇子提取物（P=0.029）、L-半胱氨酸（P=0.043）、红参（21.1%比 14.0%，P<0.05）和韩国梨汁（41.5%比 33.3%，P<0.05）在总体宿醉症状评分中的平均百分比有统计学显著降低。所有研究的耐受性结局均为低质量或极低质量，没有研究报告因 AE 而退出。
仅有关于治疗或预防酒精性宿醉的药理学活性干预措施的疗效的极低质量证据。在所研究的有限干预措施中，所有措施的耐受性均较好，且极低质量证据表明，丁香油提取物、托芬那酸和吡硫醇可能最值得进一步研究。
